Comparison of different treatment regiments in resistant Kawasaki disease
10.3760/cma.j.c141217-20191028-00369
- VernacularTitle:耐药型川崎病不同治疗方案的比较
- Author:
Yihong GUO
1
;
Haiguo YU
;
Yayuan ZHANG
;
Na HUANG
;
Le MA
Author Information
1. 南京医科大学附属儿童医院风湿免疫科 210008
- From:
Chinese Journal of Rheumatology
2020;24(7):459-462
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the different effects of different treatment regimens in resistant Kawasaki disease (KD) and to provide evidence for clinical treatment.Methods:Forty-nine inpatient children with resistant KD from July 2017 to June 2019 in Children's Hospital of Nanjing Medical University were enrolled into this study. Treatment and follow-up were still in progress. Rank sum test and χ2/Fisher test were used for statisic. Results:The incidence of resistance in infliximab group was significantly lower than that of intravenous immunoglobulin (IVIG) retreated group ( P<0.05). Sixteen cases were treated with 5 mg/kg infliximab (IFX), and 33 cases received methylprednisolone and an additional dose of IVIG. Nine cases who were resistant to IVIG and methylprednisolone were treated with IFX, 6 patients responded to IFX, 3 of them were treated with cyclosporine. Coronary artery changes were followed up. Coronary artery lesions (CALs) were improved in the IFX group, CALs occurred in 12(36%) patients received IVIG and methylprednisolone, 4 of them were improved( χ2=0.633 , P=0.426). Patients were followed up for 3-24 months, the incidence of CALs persistence was statistically significantly different between the two groups (0 vs 24%, P=0.021]. Conclusion:IFX might be an effective and tolerable treatment for resistant KD.
